Loading...

Jennifer Clarke, MD, MPH

Title(s)Professor, Neurology
SchoolSchool of Medicine
Phone415-353-2383
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Education and Training
    Memorial Sloan-Kettering Cancer Center, New York2008Neuro Oncology Fellowship
    University of California, San Francisco, San Francisco2006Neurology
    St. Mary's Medical Center, San Francisco, San Francisco2003Intern, Medicine
    University of California, San Francisco, San FranciscoMD2002
    University of California, Berkeley, BerkeleyMPH2001Health Policy and Management
    California Institute of Technology , PasadenaB.S.1995Chemistry
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Jennifer L. Clarke, MD, MPH
    Professor of Clinical Neurology and Neurological Surgery
    Division of Neuro-Oncology
    Principal Investigator, Brain Tumor Research Center

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019 Sep 12. PMID: 31515627.
      View in: PubMed
    2. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol Pract. 2019 Sep; 6(5):364-374. PMID: 31555451.
      View in: PubMed
    3. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. PMID: 30742122.
      View in: PubMed
    4. Morrison MA, Hess CP, Clarke JL, Butowski N, Chang SM, Molinaro AM, Lupo JM. Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. J Magn Reson Imaging. 2019 Sep; 50(3):868-877. PMID: 30663150.
      View in: PubMed
    5. Stiner RK, Clarke JL, Sinha N, Chan J, Letourneau JM, Niemasik EE, Rabbitt JE, Chang SM, Butowski NA, Prados MD, Rosen MP. Attitudes toward fertility and fertility preservation in women with glioma. Neurooncol Pract. 2019 May; 6(3):218-225. PMID: 31386027.
      View in: PubMed
    6. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 2018 Nov; 140(2):477-483. PMID: 30151703.
      View in: PubMed
    7. Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA. The genetic landscape of ganglioglioma. Acta Neuropathol Commun. 2018 06 07; 6(1):47. PMID: 29880043.
      View in: PubMed
    8. Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol. 2018 04 09; 20(5):632-641. PMID: 29077933.
      View in: PubMed
    9. Leeper HE, Acquaye AA, Bell S, Clarke JL, Forst D, Laack NN, Link MJ, Taylor JW, Armstrong TS. Survivorship care planning in neuro-oncology. Neurooncol Pract. 2018 Mar; 5(1):3-9. PMID: 31386011.
      View in: PubMed
    10. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. PMID: 29074604.
      View in: PubMed
    11. Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639. PMID: 28759109.
      View in: PubMed
    12. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610. PMID: 28233053.
      View in: PubMed
    13. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251. PMID: 27571885.
      View in: PubMed
    14. Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines. 2016 Oct 31; 4(4). PMID: 28536391.
      View in: PubMed
    15. Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017 01; 19(1):78-88. PMID: 27282397.
      View in: PubMed
    16. Fogh SE, Johnson DR, Barker FG, Brastianos PK, Clarke JL, Kaufmann TJ, Oberndorfer S, Preusser M, Raghunathan A, Santagata S, Theodosopoulos PV. Case-Based Review: meningioma. Neurooncol Pract. 2016 Jun; 3(2):120-134. PMID: 31386096.
      View in: PubMed
    17. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200. PMID: 26493740.
      View in: PubMed
    18. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253. PMID: 25856113.
      View in: PubMed
    19. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5. PMID: 26181937.
      View in: PubMed
    20. Johnson DR, Fogh SE, Giannini C, Kaufmann TJ, Raghunathan A, Theodosopoulos PV, Clarke JL. Case-Based Review: newly diagnosed glioblastoma. Neurooncol Pract. 2015 Sep; 2(3):106-121. PMID: 31386093.
      View in: PubMed
    21. Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361. PMID: 25793136.
      View in: PubMed
    22. Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64. PMID: 25219810.
      View in: PubMed
    23. Clarke JL. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol. 2014 Oct; 24(4):273-8. PMID: 25219812.
      View in: PubMed
    24. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40. PMID: 25208478.
      View in: PubMed
    25. Griffin TL, Pallan MJ, Clarke JL, Lancashire ER, Lyon A, Parry JM, Adab P. Process evaluation design in a cluster randomised controlled childhood obesity prevention trial: the WAVES study. Int J Behav Nutr Phys Act. 2014 Sep 10; 11:112. PMID: 25212062.
      View in: PubMed
    26. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90. PMID: 24637230.
      View in: PubMed
    27. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62. PMID: 24670608.
      View in: PubMed
    28. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9. PMID: 24335700.
      View in: PubMed
    29. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6. PMID: 23095230.
      View in: PubMed
    30. Nagpal S, Clarke JL. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45. PMID: 22961188.
      View in: PubMed
    31. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42. PMID: 22810130.
      View in: PubMed
    32. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70. PMID: 21841523.
      View in: PubMed
    33. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5. PMID: 22089116.
      View in: PubMed
    34. Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31. PMID: 22290254.
      View in: PubMed
    35. Clarke JL, Deangelis LM. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27. PMID: 22230516.
      View in: PubMed
    36. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80. PMID: 21969507.
      View in: PubMed
    37. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9. PMID: 21865399.
      View in: PubMed
    38. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. PMID: 21813511.
      View in: PubMed
    39. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6. PMID: 20146086.
      View in: PubMed
    40. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. PMID: 20167815.
      View in: PubMed
    41. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 Aug 10; 27(23):3861-7. PMID: 19506159.
      View in: PubMed
    42. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009 May; 9(3):241-6. PMID: 19348713.
      View in: PubMed
    43. Clarke JL, Johnston SC, Farrant M, Bernstein R, Tong D, Hemphill JC. External validation of the ICH score. Neurocrit Care. 2004; 1(1):53-60. PMID: 16174898.
      View in: PubMed